I select in vitro diagnostic instruments by starting with the laboratory’s test menu and workflow rather than choosing equipment by brand name or headline specifications. The right instrument must support the required assay format, sample volume, throughput, analytical performance, connectivity, regulatory pathway, maintenance plan, and total cost of ownership. For example, a laboratory running microplate immunoassays may need a microplate reader with defined optical wavelengths, while a molecular laboratory may prioritize thermal cycling, fluorescence detection, contamination control, and software traceability.
For more information, please visit our website.
My practical approach is to define the intended use, convert it into measurable specifications, verify performance with documented evidence, and then compare suppliers using a lifecycle-cost model. I also check whether the instrument can be validated within the laboratory’s quality system and whether the supplier can provide installation, training, service, spare parts, and technical documentation. This framework reduces the risk of buying equipment that appears capable but does not fit the laboratory’s actual testing process.
The first question is not “Which instrument is the most advanced?” but “What testing problem must the instrument solve?” I document the sample types, assays, daily workload, peak workload, required turnaround time, result-reporting process, and operator skill level. I also record whether the instrument will be used for screening, quantitative measurement, qualitative interpretation, confirmatory testing, or research and development.
This distinction matters because a low-volume laboratory may benefit from a flexible benchtop platform, whereas a high-volume laboratory may require automation, multiple loading positions, barcode handling, and laboratory information system connectivity. A laboratory performing infectious-disease testing may also need stronger controls for contamination prevention and result traceability than a facility using the instrument for nonclinical research. The intended use should be documented before requesting quotations.
In vitro diagnostic instruments are not a single equipment category. They include systems for immunoassay, clinical chemistry, hematology, molecular diagnostics, microbiology, coagulation, sample preparation, and integrated automation. I compare the instrument’s actual role in the workflow, because two instruments with similar throughput figures may have very different sample preparation, detection, calibration, and reporting requirements.
| Instrument category | Typical workflow need | Specifications to review |
|---|---|---|
| Microplate reader | ELISA, absorbance, fluorescence, or luminescence assays | Plate format, wavelength range, optical accuracy, shaking, incubation, and software |
| Clinical chemistry analyzer | Routine measurement of biochemical analytes | Tests per hour, reaction volume, reagent handling, calibration, carryover, and sample positions |
| Hematology analyzer | Cell counting and hematological parameter analysis | Parameters, sample aspiration volume, throughput, flags, quality control, and consumables |
| Molecular diagnostic system | Nucleic-acid amplification and detection | Thermal control, fluorescence channels, contamination controls, software, and result traceability |
| Coagulation analyzer | Clotting and hemostasis testing | Detection principle, channels, reagent stability, sample capacity, and quality-control functions |
These categories are a starting point rather than a substitute for assay-specific verification. I confirm that the instrument is compatible with the manufacturer’s intended reagents, calibrators, controls, sample containers, and operating conditions. If the laboratory plans to use third-party reagents or develop laboratory-developed procedures, I require a separate assessment of validation, interoperability, and technical support.
The U.S. Food and Drug Administration explains that in vitro diagnostic products include reagents, instruments, and systems intended for the examination of specimens outside the body, which is why intended use and regulatory status should be reviewed together. FDA: In Vitro Diagnostics.
After defining the workflow, I create a requirements matrix. Each requirement should be classified as mandatory, preferred, or optional, and each supplier should respond with documentary evidence rather than a general statement such as “high performance.” This makes quotations easier to compare and reveals where a lower purchase price may involve higher operating costs or manual work.
Throughput should be calculated from real workload, including loading, preparation, calibration, quality-control runs, repeat tests, and unloading. A 96-well plate, for example, does not necessarily provide 96 patient results because wells may be allocated to calibrators, controls, blanks, and repeats. I calculate expected utilization using routine volume and peak volume rather than relying only on the maximum number stated in a brochure.
Sample volume can affect consumable cost, assay feasibility, and suitability for pediatric or limited-volume specimens. I record the required working volume in microliters, allowable dead volume, container types, clot or liquid-level detection, dilution capability, and barcode options. For reagent systems, I review onboard stability, refrigeration requirements, lot tracking, calibration frequency, and whether open-container time is documented.
The key performance parameters depend on the assay, but commonly include precision, analytical measuring range, limit of detection, carryover, linearity, interference, and result comparability. I ask suppliers to identify the test method, sample matrix, number of replicates, and acceptance criteria used for each performance claim. A specification without test conditions is difficult to interpret and should not be treated as a guaranteed result in the buyer’s laboratory.
For optical systems, I verify wavelength selection, detection channels, optical accuracy, signal range, and compatibility with the assay’s chromophore or fluorophore. Common microplate assay wavelengths include 405 nm, 450 nm, and 620 nm, but the relevant wavelengths must come from the assay protocol rather than from a generic instrument list. For thermal or molecular systems, I review temperature range, uniformity, ramp performance, fluorescence channels, and contamination-control design.
For automated systems, I also assess robotic positioning, aspiration accuracy, mixing, wash performance, sample identification, and error recovery. A system that processes 100 tests per hour may still be unsuitable if operators must repeatedly intervene to clear consumable errors or manually transfer results. I therefore evaluate effective throughput, which is the number of reportable results produced under normal laboratory conditions.
Compliance requirements depend on the country, intended use, laboratory type, and regulatory classification. I ask the supplier to provide applicable product documentation, intended-use information, user manuals, installation requirements, maintenance instructions, and available validation support. I do not assume that a research-use instrument is automatically suitable for clinical reporting.
Data integrity should be assessed as part of instrument selection, not after installation. I review user access controls, audit trails, electronic records, result amendments, time synchronization, backup procedures, barcode traceability, and interfaces with the laboratory information system. If the instrument uses cloud services or remote support, I also ask how data are transmitted, stored, protected, and retrieved.
ISO 15189:2022 addresses requirements for quality and competence in medical laboratories, including processes that affect examination results and laboratory operations. I use the applicable edition and local accreditation requirements as a reference when defining validation, records, competence, and quality-management expectations. ISO 15189:2022 overview.
The supplier’s service model can influence laboratory uptime as much as the instrument’s technical design. I compare local response capability, remote-support procedures, preventive-maintenance intervals, engineer availability, spare-part lead times, warranty scope, and escalation procedures. I also ask whether training is included for operators, supervisors, service personnel, and quality staff.
With competitive price and timely delivery, COEI sincerely hope to be your supplier and partner.
Purchase price is only one part of the financial decision. My total-cost calculation includes the instrument, installation, validation, software, interfaces, reagents, calibrators, controls, disposables, preventive maintenance, corrective service, utilities, waste handling, training, and expected downtime. I usually model costs over 3 to 5 years, while clearly labeling assumptions because actual costs depend on workload, reagent contracts, local labor, and service conditions.
| Cost element | Buyer question |
|---|---|
| Instrument purchase | What is included, and what requires a separate quotation? |
| Consumables | What is the cost per reportable result, including controls and repeats? |
| Service | What are the warranty period, maintenance intervals, and response targets? |
| Integration | Are software licenses, interfaces, barcode readers, and validation support included? |
| Replacement risk | How long will software, spare parts, and technical support remain available? |
For international sourcing, I additionally check packaging, installation conditions, voltage and frequency, customs documentation, delivery terms, import responsibilities, and after-sales communication. I request a written quotation with validity, lead time, payment terms, warranty exclusions, minimum order quantities for consumables, and replacement-part availability. These details reduce ambiguity when comparing suppliers from different regions.
I recommend a weighted scoring model instead of selecting the lowest quotation. For example, a laboratory could assign 25% to analytical and workflow fit, 20% to compliance and documentation, 15% to integration and data management, 15% to service support, 15% to total cost, and 10% to delivery and supply continuity. The exact weights should reflect the laboratory’s risk profile and testing volume.
I distinguish a demonstration from a formal performance evaluation. A demonstration shows how the instrument operates, while verification establishes whether the system meets the laboratory’s predefined acceptance criteria under its intended conditions. The laboratory should define these criteria before testing to avoid changing the decision after seeing the results.
Maximum throughput often excludes preparation, loading, calibration, quality control, repeats, and operator intervention. I calculate the number of reportable patient results per hour under the planned workflow. If the instrument is expected to operate for 8 hours per day, I also model peak periods and planned maintenance instead of assuming uninterrupted operation.
An instrument may have an attractive purchase price but require proprietary consumables, frequent calibrations, or minimum purchase quantities. I ask for a cost-per-result estimate that includes controls, calibrators, wash solutions, reaction vessels, tips, and expected repeats. I also review whether critical consumables have alternative sources or whether the laboratory is exposed to a single-supplier risk.
Manual transcription can create additional labor and increase the opportunity for identification or reporting errors. I confirm interface protocols, barcode formats, middleware requirements, cybersecurity controls, user permissions, and responsibility for implementation. Integration should be tested with realistic workflows, including rejected samples, corrected results, instrument alarms, and network interruptions.
Terms such as “high accuracy,” “fast,” or “maintenance-free” are incomplete without test methods and operating conditions. I ask for the supporting document, applicable assay, sample matrix, number of measurements, and acceptance criteria. If evidence is unavailable, I treat the claim as unverified and assign a risk or follow-up action.
CLSI EP05 provides a widely used framework for evaluating precision of quantitative measurement procedures, while other CLSI documents address analytical measurement ranges, detection capability, and method comparison. I use the applicable laboratory and regulatory framework rather than applying one performance protocol to every instrument type. CLSI standards and documents.
I prefer a modular selection when the laboratory expects workload growth but cannot justify full automation immediately. The initial configuration should meet current mandatory requirements, while optional sample positions, software modules, automation links, or additional detection channels can be evaluated for future phases. This approach can reduce the risk of paying for unused capacity while preserving a documented expansion path.
I also recommend defining acceptance and review milestones in the purchase agreement. These may include delivery inspection, installation completion, operator training, interface testing, quality-control performance, and final handover of documentation. The buyer should identify who approves each milestone and what happens if the instrument does not meet the agreed requirements.
For laboratories operating across more than one site, standardization can simplify training, consumable management, method transfer, and service coordination. However, standardization should not override local assay requirements or regulatory constraints. I compare the benefits of common platforms against the risk of concentrating all testing on one instrument family or supplier.
When I work with a B2B supplier such as COEI, I expect the discussion to begin with a documented requirement rather than a generic product recommendation. A useful supplier response should clarify the proposed instrument configuration, compatible applications, required utilities, consumables, delivery scope, installation conditions, technical documentation, and after-sales support. Where a requirement cannot be confirmed, the supplier should identify it as pending verification.
COEI can be approached for a structured inquiry covering application, quantity, destination country, required specifications, validation expectations, and target delivery schedule. For international buyers, I recommend requesting a configuration-specific quotation instead of comparing a base-model price with a fully configured system. This makes it easier to evaluate the complete supply package, including documentation, training, packaging, logistics, and service responsibilities.
Before placing an order, I provide the supplier with the assay list, workload estimate, sample information, site conditions, preferred interface requirements, and acceptance criteria. I then ask for written confirmation of any critical specification, including wavelength, throughput, sample volume, temperature control, detection channels, software functions, and service coverage. This evidence-based exchange gives both parties a clearer basis for procurement and implementation.
The best in vitro diagnostic instrument is the one that fits the laboratory’s intended use, assay requirements, workload, quality system, data environment, and service capacity. I recommend selecting by documented evidence and total cost of ownership rather than by maximum throughput or the lowest initial quotation. A practical decision should combine workflow mapping, measurable specifications, supplier verification, technical evaluation, and a controlled implementation plan.
As a next step, prepare a one-page requirement sheet containing assay types, sample volume, daily and peak workload, turnaround time, required data interface, site conditions, mandatory performance specifications, and target delivery date. Send that information to COEI or other qualified suppliers and request a configuration-specific quotation with supporting documents, warranty terms, consumables pricing, lead time, and acceptance criteria. This process gives your laboratory a defensible basis for comparing options and selecting equipment that can support reliable long-term operation.
The company is the world’s best in vitro diagnostic instruments supplier. We are your one-stop shop for all needs. Our staff are highly-specialized and will help you find the product you need.